SCHEMBL20148071

SCHEMBL20148071

COc1ccc(NC(=O)C2C3CC2CN(C(C)C)C3)cn1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
LMNA P02545 2/20 0.48
KDM4E B2RXH2 2/20 0.48
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
HTT P42858 1/20 0.48
KMT2A Q03164 8/20 0.46
MEN1 O00255 7/20 0.46
MAPT P10636 2/20 0.46
POLB P06746 2/20 0.46
FPR3 P25089 1/20 0.45
FPR2 P25090 1/20 0.45
PABPC1 P11940 4/20 0.45
RET P07949 1/20 0.44
IDO1 P14902 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25505302 0.89 ALDH1A1 (0.45) ALDH1A1LMNAKDM4ERAB9ANPC1
SCHEMBL20068838 0.87 ALDH1A1 (0.51) ALDH1A1LMNAKDM4ERAB9ANPC1
SCHEMBL20206039 0.84 LMNA (0.49) ALDH1A1LMNAKDM4ERAB9ANPC1
SCHEMBL20070437 0.84 LMNA (0.48) ALDH1A1LMNAKDM4ERAB9ANPC1
SCHEMBL20205857 0.84 RAB9A (0.48) ALDH1A1LMNAKDM4ERAB9ANPC1
SCHEMBL20068882 0.80 RET (0.42) ALDH1A1LMNAKDM4ERAB9ANPC1
SCHEMBL20069825 0.80 KDM4E (0.48) ALDH1A1LMNAKDM4ERAB9ANPC1
SCHEMBL20068839 0.76 ALDH1A1 (0.49) ALDH1A1LMNARAB9ANPC1HTT
SCHEMBL29445396 0.73 KMT2A (0.58) ALDH1A1LMNAKDM4ERAB9ANPC1
SCHEMBL41767 0.73 KMT2A (0.58) ALDH1A1LMNAKDM4ERAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-10-15 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 ALDH1A1 2547/4885LMNA 1968/4885KDM4E 547/4885
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 ALDH1A1 2547/4885LMNA 1968/4885KDM4E 547/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 ALDH1A1 2547/4885LMNA 1968/4885KDM4E 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.